Economic Burden of treated Lower-Risk Myelodysplastic Syndromes in France: A Population-Based Study

Background

Updated data are needed to understand the current implications of Low-risk Myelodysplastic syndromes (LR-MDS) on healthcare resource use (HCRU) and associated costs. Objectives of this study were to describe these outcomes over time but also to compare costs according to transfusion dependency at baseline.